12:00 AM
 | 
Aug 29, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Xgeva denosumab regulatory update

Amgen said FDA assigned a PDUFA date of April 26, 2012, for an sBLA for Xgeva denosumab to prevent bone metastases in men with castration-resistant prostate cancer (CRPC). Denosumab is approved in...

Read the full 136 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >